Levison J C, Kent G N, Worth G K, Retallack R W
Endocrinology. 1977 Dec;101(6):1898-901. doi: 10.1210/endo-101-6-1898.
Osteomalacia has been shown to be associated with long-term anticonvulsant therapy. Anticonvulsants modify the hepatic metabolism of vitamin D3 and decrease serum 25-hydroxy-vitamin D3 (25-OH-D3) levels. We have confirmed this and have shown that diphenylhydantoin (DPH) and phenobarbitone (PB) enhance the activity of kidney 25-hydroxy-vitamin D3-1alpha-hydroxylase (1-hydroxylase) in the chicken. Thus, anticonvulsant osteomalacia may not be due to a lack of the active metabolite of vitamin D, 1,25-dihydroxyvitamin D3 (1,25 (OH) 2D3).
骨软化症已被证明与长期抗惊厥治疗有关。抗惊厥药会改变维生素D3的肝脏代谢,并降低血清25-羟基维生素D3(25-OH-D3)水平。我们已经证实了这一点,并表明苯妥英(DPH)和苯巴比妥(PB)可增强鸡肾脏中25-羟基维生素D3-1α-羟化酶(1-羟化酶)的活性。因此,抗惊厥药所致的骨软化症可能并非由于缺乏维生素D的活性代谢产物1,25-二羟基维生素D3(1,25(OH)2D3)。